Literature DB >> 7908302

Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status.

N C Phillips1, L Gagne, C Tsoukas, J Dahman.   

Abstract

Immunoliposomes were prepared from dipalmitoylphosphatidylcholine, dimyristoylphosphatidylglycerol, biotinylated PE, and surface-linked avidin-biotinylated GK1.5 monoclonal rat (anti-mouse CD4) IgG or F(ab)2. Anti-CD4 immunoliposomes bound quantitatively to CD4+ PBMC's in vitro. Intravenous injection of mice with 1 mumol anti-CD4 immunoliposomes resulted in targeting to a significant proportion (> 75%) of CD4+ PBMCs. Repeated administration of anti-CD4 immunoliposomes induced significant levels of anti-GK 1.5 IgG Ab, with concomitant reductions in immunoliposome plasma t1/2 and targeting efficacy, and increased volumes of distribution. The immunogenicity of the immunoliposome was enhanced if GK1.5 F(ab)2 instead of IgG was used as the targeting ligand. Lipophilic poly(ethylene glycol) derivatives incorporated into the immunoliposomes did not affect targeting efficiency but significantly enhanced immunogenicity. These results demonstrate that IgG or F(ab)2 immunoliposomes are highly immunogenic and that targeting in vivo is conditional on the immune status of the host.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908302

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.

Authors:  G A Koning; H W Morselt; A Gorter; T M Allen; S Zalipsky; J A Kamps; G L Scherphof
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride.

Authors:  H Heiati; N C Phillips; R Tawashi
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

Review 3.  RNA interference: a potent tool for gene-specific therapeutics.

Authors:  Thomas E Ichim; Mu Li; Hua Qian; Igor A Popov; Katarzyna Rycerz; Xiufen Zheng; David White; Robert Zhong; Wei-Ping Min
Journal:  Am J Transplant       Date:  2004-08       Impact factor: 8.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.